Loading patent…
AssigneeMassachusetts Institute of Technology
InventorsRobert A. Weinberg, Clifford J. Tabin, Scott M. Bradley
Estimating the term…
Experiments designed to define the differences between an oncogene isolated from human bladder cancer cells and its corresponding proto-oncogene are described herein. By a series of in vitro recombinations, the difference was initially isolated to a 350 kb segment of DNA; sequencing defined the difference as a change in the Gly.sup.12 codon causing the p21 protein of the oncogene to contain valine at a location where the p21 protein of the proto-oncogene contained glycine. Assays for detecting carcinogenesis based on such differences are also described. In one type of assay, a restriction enzyme specific for either the altered or non-altered DNA segment of the genes are employed to detect carcinogenesis. In another type of assay, seralogical reagents, such as antibody specific for either p21 protein expressed from the proto-oncogene or oncogene, or a common site therein, are described.
In an assay for detecting the mutation of a proto-oncogene to an oncogene:
A method of detecting whether a proto-oncogene has been mutated into an oncogene, comprising:
An essay for human bladder cancer in test cells, comprising:
An assay for carcinogensis caused by mutation of a proto-oncogene into an oncogene, comprising:
Dependencies are inferred from the claim text.